2024
Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting
Nadim M, Kellum J, Forni L, Francoz C, Asrani S, Ostermann M, Allegretti A, Neyra J, Olson J, Piano S, VanWagner L, Verna E, Akcan-Arikan A, Angeli P, Belcher J, Biggins S, Deep A, Garcia-Tsao G, Genyk Y, Gines P, Kamath P, Kane-Gill S, Kaushik M, Lumlertgul N, Macedo E, Maiwall R, Marciano S, Pichler R, Ronco C, Tandon P, Velez J, Mehta R, Durand F. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. Journal Of Hepatology 2024, 81: 163-183. PMID: 38527522, PMCID: PMC11193657, DOI: 10.1016/j.jhep.2024.03.031.Peer-Reviewed Original ResearchAcute Disease Quality InitiativeInternational Club of AscitesAcute kidney injuryHRS-AKIQuality InitiativeHepatorenal syndromePost-discharge follow-upKidney injuryMultidisciplinary consensus meetingRisk of progression to chronic kidney diseaseProgression to chronic kidney diseasePhenotypes of acute kidney injuryFollow-up of patientsBridge to liver transplantationIncreased in-hospital morbidityIn-hospital morbidityPost-discharge follow-up of patientsChronic kidney diseaseMortality riskConsensus meetingInternational ClubCurative optionSplanchnic vasoconstrictorsAdvanced cirrhosisLiver transplantationHepatorenal Syndrome Type 1: Diagnosis and Treatment
Belcher J. Hepatorenal Syndrome Type 1: Diagnosis and Treatment. Advances In Kidney Disease And Health 2024, 31: 100-110. PMID: 38649214, DOI: 10.1053/j.akdh.2023.05.001.Peer-Reviewed Original ResearchConceptsAcute kidney injuryHepatorenal syndromeKidney injuryFunctional acute kidney injuryUrinary biomarkers of kidney injuryAssociated with significant morbidityFractional excretion of sodiumNeutrophil Gelatinase-Associated LipocalinDiagnostic criteriaBiomarkers of kidney injuryMultiple urinary biomarkersOptimal dosing strategiesExcretion of sodiumPoint-of-care ultrasoundAccurate differential diagnosisAnalog of vasopressinSets of diagnostic criteriaAdvanced cirrhosisAlbumin administrationSignificant morbidityVolume resuscitationTherapeutic optionsDosing strategiesFractional excretionDifferential diagnosis
2023
Controversies regarding albumin therapy in cirrhosis
Trebicka J, Garcia-Tsao G. Controversies regarding albumin therapy in cirrhosis. Hepatology 2023, 81: 288-303. PMID: 37540192, PMCID: PMC11643133, DOI: 10.1097/hep.0000000000000521.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSpontaneous bacterial peritonitisBacterial peritonitisAcute kidney injuryLarge-volume paracentesisSerum albumin levelChronic liver diseaseUse of albuminHepatorenal syndromeAdvanced cirrhosisAlbumin infusionKidney injuryAlbumin therapyAlbumin levelsAlbumin useProinflammatory stateLiver diseasePatient selectionVolume overloadPoor outcomeHigh oxidative stressCirrhosisPathophysiological relevanceOxidative stressPeritonitisAlbumin
2021
Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward
Belcher JM, Parada XV, Simonetto DA, Juncos LA, Karakala N, Wadei HM, Sharma P, Regner KR, Nadim MK, Garcia-Tsao G, Velez JCQ, Parikh SM, Chung RT, Allegretti AS, Investigators H. Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward. American Journal Of Kidney Diseases 2021, 79: 737-745. PMID: 34606933, DOI: 10.1053/j.ajkd.2021.08.016.Peer-Reviewed Original ResearchConceptsAcute kidney injuryHepatorenal syndromeRespiratory adverse eventsPrimary end pointFirst-line therapyMean arterial pressureSympathetic nervous systemSynthetic vasopressin analogueAdvanced cirrhosisHRS reversalAldosterone systemKidney injuryLack of evidenceAdverse eventsMortality benefitPortal pressureArterial pressureFulminant formSplanchnic systemSignificant morbidityRenal vasculatureVasodilatory substancesApparent increased rateTerlipressinCONFIRM trials
2018
PRO: Patients With Advanced Cirrhosis and Portal Vein Thrombosis Should Receive Anticoagulation
To UK, Garcia‐Tsao G. PRO: Patients With Advanced Cirrhosis and Portal Vein Thrombosis Should Receive Anticoagulation. Clinical Liver Disease 2018, 12: 74-79. PMID: 30988915, PMCID: PMC6385918, DOI: 10.1002/cld.717.Peer-Reviewed Original Research
2016
Clinical implications of Paracoccus yeeii bacteremia in a patient with decompensated cirrhosis
Sack J, Peaper DR, Mistry P, Malinis M. Clinical implications of Paracoccus yeeii bacteremia in a patient with decompensated cirrhosis. IDCases 2016, 7: 9-10. PMID: 27920982, PMCID: PMC5133649, DOI: 10.1016/j.idcr.2016.11.008.Peer-Reviewed Case Reports and Technical NotesThird-generation cephalosporinsDecompensated cirrhosisVariceal hemorrhageGeneration cephalosporinsProphylactic antimicrobial treatmentDrug-resistant organismsAdvanced cirrhosisGastrointestinal hemorrhageClinical sepsisNegative patientsRare infectionUncommon organismsInfectious sourceCirrhosisPatientsResistant organismsAntimicrobial treatmentClinical implicationsHemorrhageNegative organismsBacteremiaFirst caseInfectionCephalosporinsThe 3‐month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis
Bajaj JS, Reddy KR, Tandon P, Wong F, Kamath PS, Garcia‐Tsao G, Maliakkal B, Biggins SW, Thuluvath PJ, Fallon MB, Subramanian RM, Vargas H, Thacker LR, O'Leary JG, Disease N. The 3‐month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology 2016, 64: 200-208. PMID: 26690389, PMCID: PMC4700508, DOI: 10.1002/hep.28414.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseNosocomial infectionsLiver diseaseEnd-stage Liver Disease cohortEnd-stage liver disease (MELD) scoreSmall single-center studiesLarge North American cohortHigher readmission riskInfection-related readmissionLiver disease cohortPercent of readmissionsLiver Disease scoreSingle-center studyMultivariable logistic regressionNorth American cohortNorth American ConsortiumIndex admissionNonelective indicationsAdvanced cirrhosisProphylactic antibioticsCirrhosis severityInhibitor useReadmission ratesMonths postdischargeReadmission riskSecondary Prophylaxis in Special Patient Populations
Reiberger T, Moreau R, Ripoll C, Albillos A, Augustin S, Salerno F, Abraldes J, Garcia-Tsao G. Secondary Prophylaxis in Special Patient Populations. 2016, 317-332. DOI: 10.1007/978-3-319-23018-4_32.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSecondary prophylaxisRefractory ascitesVariceal bleedingSurvival benefitClinical nonrespondersClear precipitating eventProphylaxis of varicealBeta-blocker therapyBeta-blocker treatmentEndoscopic band ligationSpecial patient populationsAdvanced cirrhosisNSBB therapyVariceal rebleedingArterial hypotensionCirrhotic patientsFurther decompensationSerum creatinineBand ligationPatient populationProphylaxisHigh riskCurrent evidencePatientsAscites
2015
Acute Kidney Injury in Liver Disease: Role of Biomarkers
Belcher JM. Acute Kidney Injury in Liver Disease: Role of Biomarkers. Advances In Kidney Disease And Health 2015, 22: 368-375. PMID: 26311598, DOI: 10.1053/j.ackd.2015.06.009.BooksConceptsAcute kidney injuryEtiology of AKINeutrophil Gelatinase-Associated LipocalinAcute tubular necrosisGelatinase-Associated LipocalinHepatorenal syndromeKidney injuryPrerenal azotemiaTubular necrosisFractional excretionInterleukin-18Urinary neutrophil gelatinase-associated lipocalinProgression of AKIKidney tubular injurySetting of cirrhosisOverall poor outcomeRole of biomarkersStandard diagnostic toolAdvanced cirrhosisAKI etiologyCommon complicationTubular injuryCommon etiologyLiver diseasePoor outcome
2012
Serum levels of soluble CD25 as a marker for hepatocellular carcinoma
CABRERA R, FITIAN A, ARARAT M, XU Y, BRUSKO T, WASSERFALL C, ATKINSON M, LIU C, NELSON D. Serum levels of soluble CD25 as a marker for hepatocellular carcinoma. Oncology Letters 2012, 4: 840-846. PMID: 23205111, PMCID: PMC3506698, DOI: 10.3892/ol.2012.826.Peer-Reviewed Original ResearchSerum levelsEarly hepatocellular carcinomaHepatocellular carcinomaHCC presenceSoluble CD25Pg/Levels of sCD25Healthy control subjectsNovel predictive markerAdvanced cirrhosisPresent study studyAdvanced fibrosisTumor burdenTumor stageControl subjectsHCC patientsPredictive markerImmune factorsGlobal unmet needLarge cohortSCD25PatientsSmall seriesUnmet needSignificant positive correlation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply